Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology

Gabriele Kembuan(Massachusetts General Hospital), Max Jan(Broad Institute)

Trends in cancer

February 13, 2024

10.1016/j.trecan.2024.01.003

Cited by 27

Related Papers

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide

|Science Translational Medicine|2021|257

Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7

|Leukemia|2023|6

Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors

|Blood|2019|0